Emerging treatments
The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma. Ma H et al. Acta Oncol. 2017 Aug 22:1-7. doi: 10.1080/0284186X.2017.1364868. [Epub ahead of print]. Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services. Popat R et al. Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14897. [Epub ahead of…